This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Drug Enforcement Administration (DEA) will move to reclassify cannabis — a historic shift that could have wide ripple effects across the country. What could the implications be for patients on their medical cannabis journey? Rescheduling would stand to have the largest impact on cannabis research and business taxes.
Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety. A Vicious Circle.
For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. We are absolutely ecstatic,” George Hodgin, the CEO of the Castroville, California based Biopharmaceutical Research Co. BRC) told The Cannigma this week.
Epidiolex is the first drug the FDA has approved that contains a substance derived from marijuana, and it is also the first drug approved by the FDA to be used to treat patients with Dravet syndrome. Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. In the recent case Hemp Industries Associations v.
The National Academies of Sciences reports that PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. The psychological symptoms that develop because of the trauma affect mood, cognition, memories (both suppression and the inability to form new memories) and physical health.
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.
(OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.
Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. cannabis researchers. For years, NIDA and the DEA have promised to open up the sourcing of federally-approved research cannabis.
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.
Did we ever stop to think that if we could legally utilize the plants in the first place that perhaps we wouldn’t develop terminal illnesses at such a high rate? A Push by Patients. Along with patients, a Seattle-based palliative care physician by the name of Dr. Sunil Aggarwal was also named in the lawsuit.
The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. “DEA
MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. The partnership will initiate the development of CBD and THC oral thin films for CURE’s clinical studies targeted at advancing veteran health.
Researchers believe cannabis contains over 100 unique chemical compounds! Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential.
We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.
Democratic leaders in both chambers of Congress have come up with a new plan that would make it easier for scientists to access high-quality cannabis for research. . The provision would require the US transportation secretary to develop a public report on the risk of cannabis-impaired driving within two years of the bill’s passage.
With respect to ketamine infusion therapy (which is the prime time attraction of ketamine clinics), the medical research based promise is for treatment of chronic neuropathic pain, chronic pain (instead of opioids), and various medication-resistant mental health disorders, including depression, bi-polar disorder, and PTSD (among others).
Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate. D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted.
Denver is expanding Alzheimer’s research through the efforts of local company MedPharm. . The company plans to move forward with research efforts through a special Schedule I Researcher Licenses given specifically to the company by the Drug Enforcement Administration. Denver Company Moves Forward with Research License .
Panacea”), a leading United States biotechnology company focused on developing new therapeutic, cultivation, extraction and isolation techniques for high value natural products such as psychedelic-containing lifeforms and cannabis. is a Canadian biotechnology company providing cannabis testing and research services.
Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybin-containing mushrooms for authorized research purposes. market for research purposes is absolutely key for us as we look to expand our business in 2022,” he adds. “With their track-record of working with the U.S.
According to the Drug Enforcement Administration (DEA) website , magic mushrooms are recognizable by their slender stems, which are “topped by caps with dark gills on the underside.” has funneled her energy into simplifying the process of conducting psychedelic research. Research efforts are ongoing. milligrams.
On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation. POPLAR will publish original law and policy research. What barriers exist to conducting psychedelics research?
Trulieve offers Delta-8 in its TruPod vaporizer cartridges and TruClear Syringes, says Beau Williamson, Trulieve director of research and development. Typically, patients may experience some of the same analgesic and antiemetic effects as Delta-9,” he adds. RELATED: Dr. Ethan Russo Endorses 1% THC Limit for Hemp. RELATED: U.S.
Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. Joyce Cutler, Texas the Latest State to Legalize Psychedelic Medical Research, BLOOMBERG LAW (June 23, 2021), available at [link].
On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). Background.
When it comes to scientific research and the way of Delta-8-THC, it is scarce. An outdated study from the early 1990s conducted on chemotherapy patients that were children showed just like Delta-9 that Delta-8 helped prevent vomiting. The DEA is Already Interfering. Way to go, DEA, on jumping the gun showing your true colors.
By: James Holley, Molecular Biologist, Scientific Officer, Mike Robinson, Co-founder, Research Institute, and Dr. David Ostrow, M.D., Research Director. International Cannabinoid Cancer Research Institute (Draft 5). One patient died but it was ruled to be part of the course of their disorder and not a drug effect.
A recommendation from a physician is simply permission (‘recommendation’) for the patient to use cannabis, which can be obtained in any state where medical marijuana is legal. Epidiolex, an FDA-approved medication containing CBD (cannabidiol), has been listed as Schedule 5 by the DEA since June 25th, 2019.
MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . The full statement.
According to Dr. Sue Sisley, President of the Scottsdale Research Institute and longtime cannabis researcher, this new study is sorely needed in the community. Veterans are demanding objective cannabis drug developmentresearch, and the state of Michigan is fulfilling our collective obligation to our beloved Veteran community.”.
The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.
as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Later that year, Doblin sued the DEA for the first time.
Named because it is the result of the joining two different chemical types – a ketone and an amine, ketamine was developed in 1962 as an alternative dissociative anesthetic drug to the potently hallucinogenic phencyclidine, known more commonly as PCP. It was becoming clear that another class of anesthetics was needed.
Dr. Titus has been involved in the development and investment of several industry-leading cannabis and industrial hemp businesses during his most recent career. Dr. Titus developed several prominent cannabis companies, including HempMeds, KannaLife Sciences Inc, and Kannaway, LLC.
Trulieve offers Delta-8 in its TruPod vaporizer cartridges and TruClear Syringes, says Beau Williamson, Trulieve director of research and development. Typically, patients may experience some of the same analgesic and antiemetic effects as Delta-9,” he adds. RELATED: Dr. Ethan Russo Endorses 1% THC Limit for Hemp. RELATED: U.S.
Trulieve offers Delta-8 in its TruPod vaporizer cartridges and TruClear Syringes, says Beau Williamson, Trulieve director of research and development. Typically, patients may experience some of the same analgesic and antiemetic effects as Delta-9,” he adds. RELATED: Dr. Ethan Russo Endorses 1% THC Limit for Hemp. RELATED: U.S.
This cautionary tale is premised on the same goal that some dispensary owners, manufacturers, and stockholders are hypervigilant on, to the detriment of hemp patients. While the FDA continues to choke the progression of research and scientific developments regarding marijuana, it simultaneously cracks down on the big players of our industry.
But in an email correspondence conducted as research for this article, EFSA denies issuing any statement in relation to CBD in Spain. Food and Drug Administration (FDA) earlier this year, and convince the DEA to reclassify CBD from a Schedule I (most restrictive category) to a Schedule V drug (least restrictive category.)
It aims to turn the plants’ chemical compounds into 2,500 5-milliliter bottles – the size of a teaspoon – of cannabis oil and sublingual drops for clinical trials among volunteer patients as early as July. It remains to be seen whether the Drug Enforcement Authority, or DEA, will designate cannabis zones for these farmers.
North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Watch Video: The Press Release. NEWS PROVIDED BY. Numinus Wellness Inc. .
Marijuana Fights Cancer and Helps Manage Side Effects, Researchers Find. She had been screening brain cancer cells because they grow faster than normal cell lines and thus are useful for research purposes. The ID -1 gene is active during human embryonic development, after which it turns off and stays off.
The informed patients, cannabis industry employees, and clinicians find it equally difficult to keep updated on Florida’s latest medical marijuana program news and changes. . In light of all this state cannabis information overload, what are some of the reasons a patient ultimately chooses a qualified personal cannabis physician? .
Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Further, substances in these scheduling categories are only available to patients under the prescription of a physician – therefore making such a classification inapplicable to cannabis in those states that regulate its adult use.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content